标题
Acute myeloid leukemia: 2019 update on risk-stratification and management
作者
关键词
-
出版物
AMERICAN JOURNAL OF HEMATOLOGY
Volume 93, Issue 10, Pages 1267-1291
出版商
Wiley
发表日期
2018-10-17
DOI
10.1002/ajh.25214
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults
- (2018) Stephanie B. Tsai et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
- (2018) H. Joachim Deeg et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2018) Lene Sofie Granfeldt Østgård et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Glutaminolysis is a metabolic dependency in FLT3ITDacute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
- (2018) Paolo Gallipoli et al. BLOOD
- Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study
- (2018) Lene Sofie Granfeldt Østgård et al. BLOOD
- HighNPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
- (2018) Sanjay S. Patel et al. BLOOD
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
- (2018) Raphael Itzykson et al. BLOOD
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000
- (2018) Hagop M. Kantarjian et al. CANCER
- Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California
- (2018) Gwendolyn Ho et al. CANCER
- Investigational CD33-targeted therapeutics for acute myeloid leukemia
- (2018) Roland B. Walter EXPERT OPINION ON INVESTIGATIONAL DRUGS
- NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
- (2018) Pedro Henrique Prata et al. HAEMATOLOGICA
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
- (2018) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
- (2018) Kiyomi Morita et al. JOURNAL OF CLINICAL ONCOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
- (2018) Anna B. Halpern et al. LEUKEMIA
- Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
- (2018) Ann-Kathrin Eisfeld et al. LEUKEMIA
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
- (2018) Naval Daver et al. LEUKEMIA
- New drugs in AML: uses and abuses
- (2018) Elihu H. Estey et al. LEUKEMIA
- Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
- (2018) Peter Paschka et al. LEUKEMIA
- Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study
- (2018) Yasuhiko Harada et al. LEUKEMIA RESEARCH
- Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
- (2018) Jesse J. Salk et al. NATURE REVIEWS GENETICS
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
- (2018) Pedro Henrique Prata et al. HAEMATOLOGICA
- Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
- (2018) Frederick Fasslrinner et al. Lancet Haematology
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
- (2017) Roland B. Walter et al. HAEMATOLOGICA
- CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2017) Jatinder K. Lamba et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study
- (2017) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2017) Bart L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
- (2017) Nicolaus Kröger et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission
- (2017) Xavier Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
- (2017) P Boddu et al. LEUKEMIA
- Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?
- (2017) Y Zhou et al. LEUKEMIA
- How good are we at predicting the fate of someone with acute myeloid leukaemia?
- (2017) E Estey et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
- (2017) S Jaramillo et al. Blood Cancer Journal
- Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
- (2017) Roland B. Walter et al. HAEMATOLOGICA
- Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
- (2017) Mohamed L. Sorror et al. JAMA Oncology
- Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
- (2016) A. K. Burnett et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
- (2016) G. Olombel et al. BLOOD
- Comprehensive mutational profiling of core binding factor acute myeloid leukemia
- (2016) N. Duployez et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
- (2016) M Elsawy et al. BONE MARROW TRANSPLANTATION
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
- (2016) C. Craddock et al. HAEMATOLOGICA
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?
- (2016) Daisuke Araki et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden
- (2016) G Juliusson et al. LEUKEMIA
- Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
- (2016) M Othus et al. LEUKEMIA
- Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
- (2016) M Othus et al. LEUKEMIA
- A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
- (2016) G Montalban-Bravo et al. LEUKEMIA
- Acute myeloid leukemia therapy and the chosen people
- (2016) E Estey et al. LEUKEMIA
- Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
- (2016) N Khan et al. LEUKEMIA
- Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
- (2016) U Krug et al. LEUKEMIA
- Cord-Blood Transplantation in Patients with Minimal Residual Disease
- (2016) Filippo Milano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
- (2016) George S. Laszlo et al. Oncotarget
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
- (2016) Koichi Takahashi et al. Oncotarget
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
- (2016) C. Craddock et al. HAEMATOLOGICA
- Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation
- (2016) Stephanie J. Lee et al. JAMA Oncology
- Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
- (2015) Bruno C. Medeiros et al. ANNALS OF HEMATOLOGY
- What came first: MDS or AML?
- (2015) M. J. Walter BLOOD
- Hematopoietic stem cell transplantation for patients with AML in first complete remission
- (2015) J. J. Cornelissen et al. BLOOD
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia
- (2015) E. Estey et al. BLOOD
- Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia
- (2015) Anna B. Halpern et al. BLOOD
- Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML
- (2015) T. N. Wong et al. BLOOD
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- (2015) R. B. Walter et al. HAEMATOLOGICA
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
- (2015) Xueyan Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance ofNPM1Mutations in the Absence ofFLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
- (2015) Fabiana Ostronoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
- (2015) J Desoutter et al. LEUKEMIA
- New drug approvals in acute myeloid leukemia: what’s the best end point?
- (2015) E Estey et al. LEUKEMIA
- Immunotherapy for Acute Myeloid Leukemia
- (2015) Felix S. Lichtenegger et al. SEMINARS IN HEMATOLOGY
- Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- (2015) R. B. Walter et al. HAEMATOLOGICA
- Alternative donor transplantation for adults with acute leukemia
- (2014) Frederick R. Appelbaum BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- (2014) Gail J. Roboz et al. JOURNAL OF CLINICAL ONCOLOGY
- Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
- (2014) Mohamed L. Sorror et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial
- (2014) M Lazenby et al. LEUKEMIA
- Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
- (2014) Monique Terwijn et al. PLoS One
- Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
- (2013) S. Bertoli et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
- (2013) B. Lowenberg BLOOD
- The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA
- (2013) R. F. Schlenk et al. BLOOD
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
- (2013) E. Jourdan et al. BLOOD
- MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
- (2013) H.-H. Zhu et al. BLOOD
- Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
- (2013) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission
- (2013) Raya Mawad et al. JOURNAL OF CLINICAL ONCOLOGY
- Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
- (2013) M Othus et al. LEUKEMIA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms
- (2012) Valentina Nardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
- (2011) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2011) Eric J. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
- (2010) F. Ravandi et al. BLOOD
- Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
- (2010) Celeste Bello et al. CANCER
- Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
- (2010) Ted A. Gooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
- (2008) M. A. Sekeres et al. BLOOD
- Relapse and death during first remission in acute myeloid leukemia
- (2008) M. Yanada et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now